This article was originally published in The Gray Sheet
New CEO effective May 7 is Frank Fischer, who served as president and CEO of Ventritex between 1987 and 1997. Fischer replaces company co-founder Wesley Sterman, MD, who remains chairman of the board. In announcing Fischer's appointment, the company reports that it is streamlining operations by reducing its U.S. work force by about one-third, scaling back manufacturing capacity and cutting general and administrative expenses "in several areas." The company, which manufactures the Port-Access minimally invasive system for stopped-heart coronary artery bypass grafting procedures, will book a charge related to the restructuring. Heartport says it is expanding its sales force "by moving more clinical training specialists into the field to work directly with surgical teams at their hospitals"
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.